Travere Therapeutics, Inc.

NASDAQ:TVTX

19.13 (USD) • At close March 13, 2025
Bedrijfsnaam Travere Therapeutics, Inc.
Symbool TVTX
Munteenheid USD
Prijs 19.13
Beurswaarde 1,697,592,374
Dividendpercentage 0%
52-weken bereik 5.12 - 25.29
Industrie Biotechnology
Sector Healthcare
CEO Dr. Eric M. Dube Ph.D.
Website https://www.travere.com

An error occurred while fetching data.

Over Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric

Vergelijkbare Aandelen

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

35.18 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

177.37 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.9 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

34.82 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

90.78 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

105.62 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

13.69 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

31.17 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

2.23 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)